Table 3.
Patient persistence and adherence with PCSK-9 inhibitors by use status
| Patient persistence and adherence* | On therapy (n=779) |
Discontinued therapy (n=428) |
p-value |
|---|---|---|---|
| Age | 0.13 | ||
| <40 | 12 (1.5%) | 6 (1.4%) | |
| 40-59 | 193 (24.8%) | 86 (20.2%) | |
| 60-79 | 521 (67.1%) | 297 (69.7%) | |
| More than 80 | 45 (5.8%) | 36 (8.5%) | |
| Sex (% male) | 443 (57.0%) | 193 (45.3%) | 0.0005 |
| Race | 0.10 | ||
| Caucasian/White | 706 (91.0%) | 380 (89.8%) | |
| Black | 25 (3.2%) | 21 (5.0%) | |
| Other | 28 (3.6%) | 19 (4.5%) | |
| Education | 0.02 | ||
| High school or less | 128 (16.8%) | 89 (21.0%) | |
| At least some college | 461 (60.3%) | 264 (62.3%) | |
| Graduate degree | 175 (22.9%) | 71 (16.8%) | |
| Household income | <0.0001 | ||
| <$30,000 | 97 (12.6%) | 92 (22.0%) | |
| $30,000-$69,999 | 211 (27.4%) | 123 (29.4%) | |
| >$70,000 | 288 (37.4%) | 107 (25.5%) | |
| Insurance type | 0.97 | ||
| Private | 459 (59.3%) | 257 (60.2%) | |
| Government | 290 (37.5%) | 155 (36.3%) | |
| None | 9 (1.2%) | 6 (1.4%) | |
| Insurance medication coverage | 0.43 | ||
| Full | 512 65.9%) | 281 (66.0%) | |
| Partial | 222 (28.6%) | 119 (27.9%) | |
| None | 29 (3.7%) | 22 (5.2%) | |
| Clinical characteristics | 0.01 | ||
| HeFH only | 138 (17.7%) | 87 (20.3%) | |
| ASCVD only | 288 (37.0%) | 149 (34.8%) | |
| ASCVD and HeFH | 269 (34.5%) | 115 (26.9%) | |
| Other/no response /missing | 84(10.8%) | 77 (18.0%) | |
| Months using drug | <0.0001 | ||
| Less than 1 month | 2 (0.3%) | 31 (7.4%) | |
| 1-6 months | 111 (14.4%) | 210 (50.0%) | |
| >6 months | 658 (85.3%) | 179 (42.6%) | |
| Medication adherence (% yes) | |||
| Missed or delayed doses by 1 week | 218 (28.2%) | 39 (9.3%) | <0.0001 |
| Forgotten to take dose | 283 (36.7%) | 93 (22.2%) | <0.0001 |
| Intentionally spaced doses | 47 (6.1%) | 20 (4.8%) | 0.37 |
| Skipped filling due to price | 130 (17.7%) | 203 (49.4%) | <0.0001 |
| None of the above | 309 (39.8%) | 164 (39.0%) | 0.78 |
*
9 respondents answered the question about receiving therapy, but had subsequent missing data
ASCVD, atherosclerotic cardiovascular disease; HeFH, heterozygous familial hyperlipidemia; PCSK9, proprotein convertase subtilisin/kexin type 9 inhibitors